Lexicon Pharmaceuticals | LXRX - Ebitda

Stock Price
1.31
Daily Change
0 0%
Monthly
5.65%
Yearly
66.90%
Q1 Forecast
2.01

Lexicon Pharmaceuticals reported $-49.48M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Coherus Biosciences USD -44.34M 9.82M Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Illumina USD 332M 12M Sep/2025
Insmed USD -297.13M 71.11M Jun/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 9.52B 389M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD 9.75M 17.66M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Novartis USD 5.88B 290M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Thermo Fisher Scientific USD 3.17B 335M Dec/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024